目的 探讨耐碳青霉烯鲍曼不动杆菌临床分布特点及耐药趋势,为临床合理选用抗菌药物及院感防控提供参考.方法 对2013年1月至2015年12月临床分离的耐碳青霉烯鲍曼不动杆菌分布及药敏资料回顾性分析.结果共分离鲍曼不动杆菌706株,其中耐碳青霉烯鲍曼不动杆菌523株,分离率74.1%;标本来源以痰为主(81.8%);主要分布在重症监护病房(40.3%)及呼吸内科(22.2%);耐药率总体呈上升趋势,头孢哌酮/舒巴坦耐药率最低(<38.0%),其次是米诺环素(<43.0%),对其余抗菌药物呈高度耐药性;除复方新诺明外,耐碳青霉烯鲍曼不动杆菌对常用抗菌药物的耐药率显著高于非耐碳青霉烯鲍曼不动杆菌,差异有统计学意义(P<0.01).结论 应加强耐碳青霉烯鲍曼不动杆菌耐药性监测,谨慎使用碳青霉烯类抗菌药物,采取有效措施进行防治.%Objective To investigate the clinical distribution and drug resistance of carbapenem resistant Acinetobacter baumannii in order to provide reference for clinical rational use of antibiotics and prevention and control of nosocomial infection. Method From January 2013 to December 2015,the distribution and drug sensitive data of clinical isolates of carbapenem resistant Acinetobacter baumannii were retrospectively analyzed. Results A total of 706 strains of Acinetobacter baumannii were isolated. Among them,523 strains of carbapenem resistant Acinetobacter Bauman,and the isolation rate was about 74. 1%. The main source of specimenwas sputum ( 81. 8%) . They were mainly distributed in the intensive care unit ( 40. 3%) and respiratory medicine (22. 2%) . Drug resistance rate showed an overall upward trend. The resistant rate of Cefoperazone / Shubatan was the lowest( <38. 0%) . The second was minocycline( <43. 0%) ,highly resistant to other antimicrobial agents. In addition to compound sulfame-thoxazole,the resistance rate of carbapenem resistant Acinetobacter baumannii was significantly higher than that of non carbapenem resistant Acinetobacter baumannii(P<0. 01). Conclusion We should strengthen the monitoring of drug resistance of carbapenem resistant Acinetobacter baumannii,carefully use carbapenem antibiotics,and take effective measures to prevent and control it.
展开▼
